Oncolytic Viral Therapy for Human Pancreatic Cancer Cells by Reovirus
Purpose: Pancreatic cancer has a poor prognosis and few effective therapies are available. The oncolytic effect of reovirus has been observed in cancer cells with an activated Ras signaling pathway, and pancreatic cancer may be a candidate target for reovirus because K-ras mutation is frequently fou...
Gespeichert in:
| Veröffentlicht in: | Clinical cancer research 2003-03, Vol.9 (3), p.1218-1223 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1223 |
|---|---|
| container_issue | 3 |
| container_start_page | 1218 |
| container_title | Clinical cancer research |
| container_volume | 9 |
| creator | ETOH, Tsuyoshi HIMENO, Yoshihisa MATSUMOTO, Toshifumi ARAMAKI, Masanori KAWANO, Katsunori NISHIZONO, Akira KITANO, Seigo |
| description | Purpose: Pancreatic cancer has a poor prognosis and few effective therapies are available. The oncolytic effect of reovirus has been
observed in cancer cells with an activated Ras signaling pathway, and pancreatic cancer may be a candidate target for reovirus
because K-ras mutation is frequently found in pancreatic cancer.
Experimental Design: In this study, we examined the feasibility of using reovirus (serotype 3) as an antihuman pancreatic cancer agent.
Results: Reovirus was able to infect five human pancreatic cancer cell lines (Panc1, MIApaca-2, PK1, PK9, and BxPC3) in vitro . We also confirmed that the Ras activity in these cancer cell lines was elevated compared with that in the normal cell line
and that susceptibility to reovirus was associated with the Ras activity of these cells. In a unilateral murine xenograft
model using Panc1 and BxPC3 cell lines, each tumor growth was suppressed by intratumoral injection of reovirus. Furthermore,
local injection of reovirus also had systemic antitumor effects in a bilateral xenograft model using Panc1 cell line. Immunohistochemical
examination revealed that reovirus replication was observed within the tumor but not in surrounding normal tissue.
Conclusions: These results suggest that reovirus can be considered for a novel therapy against pancreatic cancer. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_73079721</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73079721</sourcerecordid><originalsourceid>FETCH-LOGICAL-h269t-941a401cb87fc38490f9337a6d1023b804d7ac0f6716fe7dac21964bf24a849b3</originalsourceid><addsrcrecordid>eNpF0E1LAzEQBuAgiq3VvyC5qKeFfDXZPcpSW6FQkep1mc0mbmQ_atJV9t8bbcXTvIeHl5k5QVM6n6uEMzk_jZmoNCGCswm6COGdECooEedoQpnkVLJ0ihabTvfNuHcavzoPDd7WxsNuxLb3eDW00OEn6LQ38EPyGI3HuWmagMsRP5v-0_khXKIzC00wV8c5Qy8Pi22-Stab5WN-v05qJrN9kgkKglBdpspqnoqM2IxzBbKihPEyJaJSoImVikprVAWa0UyK0jIBUZd8hm4PvTvffwwm7IvWBR23gc70QygUJypTjEZ4fYRD2Zqq2HnXgh-Lv8MjuDkCCBoa6-NlLvw7IRkXgkV3d3C1e6u_nDeF_v2BN8GA13WRFTy20pR_Axq8brE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73079721</pqid></control><display><type>article</type><title>Oncolytic Viral Therapy for Human Pancreatic Cancer Cells by Reovirus</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>ETOH, Tsuyoshi ; HIMENO, Yoshihisa ; MATSUMOTO, Toshifumi ; ARAMAKI, Masanori ; KAWANO, Katsunori ; NISHIZONO, Akira ; KITANO, Seigo</creator><creatorcontrib>ETOH, Tsuyoshi ; HIMENO, Yoshihisa ; MATSUMOTO, Toshifumi ; ARAMAKI, Masanori ; KAWANO, Katsunori ; NISHIZONO, Akira ; KITANO, Seigo</creatorcontrib><description>Purpose: Pancreatic cancer has a poor prognosis and few effective therapies are available. The oncolytic effect of reovirus has been
observed in cancer cells with an activated Ras signaling pathway, and pancreatic cancer may be a candidate target for reovirus
because K-ras mutation is frequently found in pancreatic cancer.
Experimental Design: In this study, we examined the feasibility of using reovirus (serotype 3) as an antihuman pancreatic cancer agent.
Results: Reovirus was able to infect five human pancreatic cancer cell lines (Panc1, MIApaca-2, PK1, PK9, and BxPC3) in vitro . We also confirmed that the Ras activity in these cancer cell lines was elevated compared with that in the normal cell line
and that susceptibility to reovirus was associated with the Ras activity of these cells. In a unilateral murine xenograft
model using Panc1 and BxPC3 cell lines, each tumor growth was suppressed by intratumoral injection of reovirus. Furthermore,
local injection of reovirus also had systemic antitumor effects in a bilateral xenograft model using Panc1 cell line. Immunohistochemical
examination revealed that reovirus replication was observed within the tumor but not in surrounding normal tissue.
Conclusions: These results suggest that reovirus can be considered for a novel therapy against pancreatic cancer.</description><identifier>ISSN: 1078-0432</identifier><identifier>EISSN: 1557-3265</identifier><identifier>PMID: 12631628</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>3T3 Cells ; Animals ; Biological and medical sciences ; Cell Line ; Genes, ras - genetics ; Humans ; Immunohistochemistry ; Medical sciences ; Mice ; Mice, Inbred BALB C ; Mutation ; Neoplasm Transplantation ; Other treatments ; Pancreatic Neoplasms - pathology ; Pancreatic Neoplasms - therapy ; ras Proteins - metabolism ; Reoviridae - genetics ; Signal Transduction ; Time Factors ; Treatment. General aspects ; Tumor Cells, Cultured ; Tumors</subject><ispartof>Clinical cancer research, 2003-03, Vol.9 (3), p.1218-1223</ispartof><rights>2003 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14623442$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12631628$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>ETOH, Tsuyoshi</creatorcontrib><creatorcontrib>HIMENO, Yoshihisa</creatorcontrib><creatorcontrib>MATSUMOTO, Toshifumi</creatorcontrib><creatorcontrib>ARAMAKI, Masanori</creatorcontrib><creatorcontrib>KAWANO, Katsunori</creatorcontrib><creatorcontrib>NISHIZONO, Akira</creatorcontrib><creatorcontrib>KITANO, Seigo</creatorcontrib><title>Oncolytic Viral Therapy for Human Pancreatic Cancer Cells by Reovirus</title><title>Clinical cancer research</title><addtitle>Clin Cancer Res</addtitle><description>Purpose: Pancreatic cancer has a poor prognosis and few effective therapies are available. The oncolytic effect of reovirus has been
observed in cancer cells with an activated Ras signaling pathway, and pancreatic cancer may be a candidate target for reovirus
because K-ras mutation is frequently found in pancreatic cancer.
Experimental Design: In this study, we examined the feasibility of using reovirus (serotype 3) as an antihuman pancreatic cancer agent.
Results: Reovirus was able to infect five human pancreatic cancer cell lines (Panc1, MIApaca-2, PK1, PK9, and BxPC3) in vitro . We also confirmed that the Ras activity in these cancer cell lines was elevated compared with that in the normal cell line
and that susceptibility to reovirus was associated with the Ras activity of these cells. In a unilateral murine xenograft
model using Panc1 and BxPC3 cell lines, each tumor growth was suppressed by intratumoral injection of reovirus. Furthermore,
local injection of reovirus also had systemic antitumor effects in a bilateral xenograft model using Panc1 cell line. Immunohistochemical
examination revealed that reovirus replication was observed within the tumor but not in surrounding normal tissue.
Conclusions: These results suggest that reovirus can be considered for a novel therapy against pancreatic cancer.</description><subject>3T3 Cells</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Cell Line</subject><subject>Genes, ras - genetics</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Mutation</subject><subject>Neoplasm Transplantation</subject><subject>Other treatments</subject><subject>Pancreatic Neoplasms - pathology</subject><subject>Pancreatic Neoplasms - therapy</subject><subject>ras Proteins - metabolism</subject><subject>Reoviridae - genetics</subject><subject>Signal Transduction</subject><subject>Time Factors</subject><subject>Treatment. General aspects</subject><subject>Tumor Cells, Cultured</subject><subject>Tumors</subject><issn>1078-0432</issn><issn>1557-3265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpF0E1LAzEQBuAgiq3VvyC5qKeFfDXZPcpSW6FQkep1mc0mbmQ_atJV9t8bbcXTvIeHl5k5QVM6n6uEMzk_jZmoNCGCswm6COGdECooEedoQpnkVLJ0ihabTvfNuHcavzoPDd7WxsNuxLb3eDW00OEn6LQ38EPyGI3HuWmagMsRP5v-0_khXKIzC00wV8c5Qy8Pi22-Stab5WN-v05qJrN9kgkKglBdpspqnoqM2IxzBbKihPEyJaJSoImVikprVAWa0UyK0jIBUZd8hm4PvTvffwwm7IvWBR23gc70QygUJypTjEZ4fYRD2Zqq2HnXgh-Lv8MjuDkCCBoa6-NlLvw7IRkXgkV3d3C1e6u_nDeF_v2BN8GA13WRFTy20pR_Axq8brE</recordid><startdate>20030301</startdate><enddate>20030301</enddate><creator>ETOH, Tsuyoshi</creator><creator>HIMENO, Yoshihisa</creator><creator>MATSUMOTO, Toshifumi</creator><creator>ARAMAKI, Masanori</creator><creator>KAWANO, Katsunori</creator><creator>NISHIZONO, Akira</creator><creator>KITANO, Seigo</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20030301</creationdate><title>Oncolytic Viral Therapy for Human Pancreatic Cancer Cells by Reovirus</title><author>ETOH, Tsuyoshi ; HIMENO, Yoshihisa ; MATSUMOTO, Toshifumi ; ARAMAKI, Masanori ; KAWANO, Katsunori ; NISHIZONO, Akira ; KITANO, Seigo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h269t-941a401cb87fc38490f9337a6d1023b804d7ac0f6716fe7dac21964bf24a849b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>3T3 Cells</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Cell Line</topic><topic>Genes, ras - genetics</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Mutation</topic><topic>Neoplasm Transplantation</topic><topic>Other treatments</topic><topic>Pancreatic Neoplasms - pathology</topic><topic>Pancreatic Neoplasms - therapy</topic><topic>ras Proteins - metabolism</topic><topic>Reoviridae - genetics</topic><topic>Signal Transduction</topic><topic>Time Factors</topic><topic>Treatment. General aspects</topic><topic>Tumor Cells, Cultured</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>ETOH, Tsuyoshi</creatorcontrib><creatorcontrib>HIMENO, Yoshihisa</creatorcontrib><creatorcontrib>MATSUMOTO, Toshifumi</creatorcontrib><creatorcontrib>ARAMAKI, Masanori</creatorcontrib><creatorcontrib>KAWANO, Katsunori</creatorcontrib><creatorcontrib>NISHIZONO, Akira</creatorcontrib><creatorcontrib>KITANO, Seigo</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>ETOH, Tsuyoshi</au><au>HIMENO, Yoshihisa</au><au>MATSUMOTO, Toshifumi</au><au>ARAMAKI, Masanori</au><au>KAWANO, Katsunori</au><au>NISHIZONO, Akira</au><au>KITANO, Seigo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Oncolytic Viral Therapy for Human Pancreatic Cancer Cells by Reovirus</atitle><jtitle>Clinical cancer research</jtitle><addtitle>Clin Cancer Res</addtitle><date>2003-03-01</date><risdate>2003</risdate><volume>9</volume><issue>3</issue><spage>1218</spage><epage>1223</epage><pages>1218-1223</pages><issn>1078-0432</issn><eissn>1557-3265</eissn><abstract>Purpose: Pancreatic cancer has a poor prognosis and few effective therapies are available. The oncolytic effect of reovirus has been
observed in cancer cells with an activated Ras signaling pathway, and pancreatic cancer may be a candidate target for reovirus
because K-ras mutation is frequently found in pancreatic cancer.
Experimental Design: In this study, we examined the feasibility of using reovirus (serotype 3) as an antihuman pancreatic cancer agent.
Results: Reovirus was able to infect five human pancreatic cancer cell lines (Panc1, MIApaca-2, PK1, PK9, and BxPC3) in vitro . We also confirmed that the Ras activity in these cancer cell lines was elevated compared with that in the normal cell line
and that susceptibility to reovirus was associated with the Ras activity of these cells. In a unilateral murine xenograft
model using Panc1 and BxPC3 cell lines, each tumor growth was suppressed by intratumoral injection of reovirus. Furthermore,
local injection of reovirus also had systemic antitumor effects in a bilateral xenograft model using Panc1 cell line. Immunohistochemical
examination revealed that reovirus replication was observed within the tumor but not in surrounding normal tissue.
Conclusions: These results suggest that reovirus can be considered for a novel therapy against pancreatic cancer.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>12631628</pmid><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-0432 |
| ispartof | Clinical cancer research, 2003-03, Vol.9 (3), p.1218-1223 |
| issn | 1078-0432 1557-3265 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_73079721 |
| source | MEDLINE; American Association for Cancer Research; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | 3T3 Cells Animals Biological and medical sciences Cell Line Genes, ras - genetics Humans Immunohistochemistry Medical sciences Mice Mice, Inbred BALB C Mutation Neoplasm Transplantation Other treatments Pancreatic Neoplasms - pathology Pancreatic Neoplasms - therapy ras Proteins - metabolism Reoviridae - genetics Signal Transduction Time Factors Treatment. General aspects Tumor Cells, Cultured Tumors |
| title | Oncolytic Viral Therapy for Human Pancreatic Cancer Cells by Reovirus |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T17%3A53%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Oncolytic%20Viral%20Therapy%20for%20Human%20Pancreatic%20Cancer%20Cells%20by%20Reovirus&rft.jtitle=Clinical%20cancer%20research&rft.au=ETOH,%20Tsuyoshi&rft.date=2003-03-01&rft.volume=9&rft.issue=3&rft.spage=1218&rft.epage=1223&rft.pages=1218-1223&rft.issn=1078-0432&rft.eissn=1557-3265&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E73079721%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=73079721&rft_id=info:pmid/12631628&rfr_iscdi=true |